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Do Shared Exposures Link the 
Lungs and Gut? Association 
Between Asthma and 
Inflammatory Bowel DiseaseImmune-mediated, inflammatory conditions of thegut (eg, inflammatory bowel disease [IBD]) and the
lungs (eg, asthma) may be driven by common factors
including the interplay between genetic risk factors and
environmental exposures that impact the microbiome.1–4
The increasing incidence of these immune-mediated con-
ditions in recent years has been attributed frequently to
the hygiene hypothesis,5 which postulates that IBD,
asthma, and related immune-mediated conditions are re-
sults of improved sanitation including clean water,
decreased family size, and improved living conditions.
These improvements in hygiene lead to decreased micro-
bial and antigenic exposures (ie, Helicobacter pylori and
helminths) early in life,6 and thus a loss of an early
opportunity to prime the immune system.
For more than 40 years, IBD has been associated with
the increased presence of multiple pulmonary disease
processes including asthma, chronic obstructive pulmo-
nary disease, and bronchiectasis.7–12 Although the
underlying pathology that links asthma and IBD is un-
known, common embryologic developmental structures
and the potential similarly abnormal response to envi-
ronmental exposures have prompted further study into
the relationship between asthma and IBD. An association
between asthma and ulcerative colitis (UC) or Crohn’s
disease (CD) has been shown previously in multiple
North American studies using large administrative
databases.7,13,14 Furthermore, an increased risk of
asthma among IBD patients was shown recently in
Taiwan, a region where IBD traditionally has not been as
prevalent.11
In this issue of Clinical Gastroenterology and
Hepatology, Kuenzig et al15 reported their findings from
a population-based, case-control study using health
administrative data from Alberta, Canada. The authors
analyzed data from a publicly funded universal health
care plan to evaluate the relationship between a pre-
existing diagnosis of asthma and the subsequent devel-
opment of IBD. Validated case definitions for UC and CD
were used, with a long backward washout period used to
exclude prevalent cases of IBD. A control population of
patients without a diagnosis of UC or CD was assigned a
random index date and oversampled to allow for a
similar length of follow-up evaluation for cases and
controls. IBD cases and controls were evaluated for a
previous diagnosis of asthma using a validated algorithm.
In both unadjusted and adjusted analysis, patients
with a pre-existing diagnosis of asthma showedincreased odds of having CD (adjusted odds ratio [OR],
1.45; 95% confidence interval [CI], 1.31–1.60). The
relationship between asthma and the development of UC
but not CD was modified by the age at IBD diagnosis.
Asthma was associated with incident UC among patients
diagnosed with UC at 16 years of age or younger
(adjusted OR, 1.49; 95% CI, 1.08–2.07) and among
patients diagnosed with UC after 40 years of age
(adjusted OR, 1.57; 95% CI, 1.31–1.89).
An important strength of this study was its
population-based design, with capture of 99% of
individuals residing in a province of more than 4 million.
In addition, the ability to link data sets to analyze
individuals over long periods of time allowed for rela-
tively long backward washout periods, which is critical
when attempting to determine the relationship between
pre-existing asthma and incident cases of UC or CD.
Another strength of this study was the use of previously
validated algorithms to identify diagnoses of both IBD
and asthma.
The authors noted a few limitations, including the
inability to adjust for unmeasured confounders such as
smoking. However, we would argue that in a study of the
association between asthma and IBD, factors such as
smoking should not be considered as confounders, but
rather as shared exposures. Similarly, even measured
covariates such as urban/rural residence, are not con-
founders and do not require adjustment. Rather, future
work should focus on the identification of such risk
factors.
Although there were a few other limitations of this
study, as discussed by the authors, the magnitude of the
effects and the consistency of these findings with mul-
tiple prior studies across different populations would
seem to suggest that the association between asthma and
IBD is valid. So, what are the implications of an associ-
ation between asthma and the subsequent development
of IBD? Let us consider this from an epidemiologic and a
clinical perspective.
If a diagnosis of asthma increases one’s risk of
developing IBD, we should consider the processes by
which this might occur. Although it seems unlikely that
asthma itself, or pulmonary inflammation in general,
could be a driver of intestinal inflammation, this could be
investigated. It also is possible that medications used to
treat asthma, such as oral or systemic steroids or bron-
chodilators, may increase the risk of IBD. Indeed, this too
warrants further investigation. Finally, and most impor-
tantly, the authors speculated that asthma and IBD may
have shared genetic pathways, environmental exposures,
or gene–environment interactions. As such, careful
review of the asthma literature may lead to new
hypotheses regarding IBD pathogenesis. These new
hypotheses will require testing through rigorous
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epidemiologic and/or genetic studies. Ultimately, an 
improved understanding of the risk factors for the 
development of asthma and IBD and/or their shared 
pathophysiological mechanisms may lead to novel stra-
tegies for the prevention, earlier detection, and/or 
treatment.
In addition to the epidemiologic implications of this 
study, we also must consider the clinical implications. 
The authors suggested that having a diagnosis of asthma 
may serve as a warning to help identify individuals who 
may benefit from earlier referral for evaluation by a 
gastroenterologist. There is precedent for this concept 
within the field of gastroenterology. Patients with 
esophageal symptoms such as dysphagia, having a 
diagnosis of an atopic condition such as asthma increases 
the risk, and hence pretest probability, of having 
eosinophilic esophagitis.16–18 In this setting, a known 
diagnosis of asthma should reduce the threshold for 
referral and endoscopic evaluation. However, regarding 
IBD and asthma, we are not yet convinced that a diag-
nosis of asthma sufficiently increases the pretest prob-
ability of having IBD in a way that should impact the 
evaluation of patients with lower gastrointestinal 
symptoms.
Another clinical area that requires further investiga-
tion is whether or how a pre-existing diagnosis of asthma 
might impact the treatment and/or outcome of IBD. Are 
there medication interactions between asthma and IBD 
treatments? Do treatments for one condition impact 
outcomes of the other, either positively or negatively?
How might a diagnosis of asthma or severity of asthma 
impact the natural history of IBD, or impact the risk of 
endoscopic procedures or surgeries? Does comorbid 
asthma impact IBD mortality? Answering these questions 
will help clinicians better care for patients with comor-
bid asthma and IBD.
In summary, Kuenzig et al15 have built on a number 
of previous studies showing an epidemiologic association 
between asthma and IBD.7,9,11,13,14,19 Future work is 
needed to understand both the epidemiologic and clinical 
implications of this finding.References
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